Aiforia Technologies Plc, Company release, July 1, 2026 09:00 p.m. EEST
Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)
Aiforia Technologies Plc has received a notification according to which the total number of Aiforia shares owned by Acme Investments SPF Sarl decreased below the threshold of five (5) percent on June 26, 2026. The combined ownership with Timo Syrjälä exceeds the five (5) percent threshold.
Total positions of Timo Syrjälä/Acme Investments SPF Sarl subject to the notification:
| % shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.59% | 5.59% | 5.59% | 37,386,604 |
| Positions of previous notification (if applicable) | 7.22% | 7.22% | 7.22% |
A: Shares and voting rights
| Number of shares and voting rights | % of shares and voting rights | |||
| Class/type of shares, ISIN code |
Direct (AML 9:5) |
Indirect (AML 9:6 and 9:7) |
Direct (AML 9:5) |
Indirect (AML 9:6 and 9:7) |
| FI4000507934 | 280,135 | 1,809,772 | 0.75% | 4.84% |
| SUBTOTAL | 2,089,907 | 5.59% | ||
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| Timo Syrjälä | 0.75% | 280,135 | |
| Acme Investments SPF Sarl | 4.84% | 1,809,772 |
Further inquiries
Antti Ojala, CFO, Aiforia Technologies Plctel. +358 40 7202448https://investors.aiforia.com
Certified AdviserUB Corporate Finance Ltdubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia's diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com